임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
40건 표시
- 1/2상모집 중· Extensive-stage Small Cell Lung Cancer (ES-SCLC)A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
리드: 노바티스
- 1/2상모집 중· Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung CancerRollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
리드: 노바티스
- 1/2상모집 중· Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
리드: 노바티스
- 1/2상모집 중· Advanced HR+/HER2- Breast CancerStudy of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
리드: 노바티스
- 1/2상모집 중· PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based ChemotherapyA Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
리드: 노바티스
- 1/2상모집 중· Progressive Metastatic Castrate Resistant Prostate CancerAn Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
리드: 노바티스
- 1/2상모집 중· Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease
리드: 노바티스
- 1/2상모집 중· Nephropathic CystinosisDFT383 in Pediatric Participants With Nephropathic Cystinosis
리드: 노바티스
- 1/2상모집 중· Generalized Myasthenia GravisStudy to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
리드: 노바티스
- 1/2상모집 중· Advanced HR+/HER2- Breast CancerStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
리드: 노바티스
- 1/2상모집 중· Relapsing Multiple SclerosisAn Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
리드: 노바티스
- 1/2상모집 중· Healthy Volunteers, Pulmonary Arterial HypertensionA Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
리드: 노바티스
- 1/2상모집 중· Sickle Cell DiseaseA Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
리드: 노바티스
- 1/2상모집 중· Philadelphia Chromosome-PositivePhase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
협력: 노바티스
- 1/2상모집 예정· Sickle Cell DiseaseCrizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia
협력: 노바티스
- 1/2상모집 예정· KRAS Mutation-Related TumorsTrametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
협력: 노바티스
- 1/2상모집 중단 (진행 중)· Systemic Lupus ErythematosusAn Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus
리드: 노바티스
- 1/2상모집 중단 (진행 중)· KRAS G12C Mutant Solid TumorsPlatform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
리드: 노바티스
- 1/2상모집 중단 (진행 중)· HER2-positive Metastatic Breast CancerClinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
협력: 노바티스
- 1/2상모집 중단 (진행 중)· Extensive Stage Small Cell Lung CancerA Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
리드: 노바티스
- 1/2상모집 중단 (진행 중)· Metastatic Uveal MelanomaA Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
리드: 노바티스
- 1/2상모집 중단 (진행 중)· Refractory or Recurrent Solid TumorSpartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults
협력: 노바티스
- 1/2상모집 중단 (진행 중)· Advanced Soft-tissue SarcomaHDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas
협력: 노바티스
- 1/2상모집 중단 (진행 중)· Anatomic Stage II Breast Cancer AJCC v8Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
협력: 노바티스
- 1/2상모집 중· Myeloid Leukemia, Philadelphia PositiveStudy to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
리드: 노바티스
- 1/2상모집 중단 (진행 중)· Prostate Cancer MetastaticA Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
리드: 노바티스
- 1/2상모집 중단 (진행 중)· Myelodysplastic SyndromesCanakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
협력: 노바티스
- 1/2상모집 중단 (진행 중)· KRAS G12C Mutant Solid TumorsStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
리드: 노바티스
- 1/2상모집 중· Acute Myeloid LeukemiaCombination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
협력: 노바티스, 화이자
- 1/2상모집 중· Advanced Solid TumorA Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
리드: 노바티스
- 1/2상모집 중단 (진행 중)· Chronic Lymphocytic LeukemiaPhase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
리드: 노바티스
- 1/2상모집 중단 (진행 중)· Breast CancerStudy of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
리드: 노바티스
- 1/2상모집 중단 (진행 중)· Severe Aplastic AnemiaEltrombopag With Standard Immunosuppression for Severe Aplastic Anemia
협력: 노바티스
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.